Overview

Study to Evaluate the Effects of Renal Impairment on the Pharmacokinetics, Safety and Tolerability of GC4419

Status:
Completed
Trial end date:
2021-04-06
Target enrollment:
Participant gender:
Summary
The study is a two-center, Phase 1, open-label, single-dose, one-period, four groups, PK study in subjects with various severities of renal impairment and matched healthy controls.
Phase:
Phase 1
Details
Lead Sponsor:
Galera Therapeutics, Inc.
Treatments:
Avasopasem manganese